Inhibitory effects of 1α,25-dihydroxyvitamin D3 on the G1-S phase-controlling machinery

Molecular Endocrinology

Volumn 15, Issue 8, 2001, Pages 1370-1380

  Jensen, Simon Skjøde ^a,b,c   Madsen, Mogens Winkel ^b   Lukas, Jiri ^a   Binderup, Lise ^b   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b LEO PHARMA A S   (Denmark)

^c Leo Pharmaceutical Products ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; CYCLIN A; CYCLIN D3; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; CALCITRIOL; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN E; CYCLINE; MESSENGER RNA; MYC PROTEIN; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

BREAST NEOPLASMS; CALCITRIOL; CDC2-CDC28 KINASES; CELL DIVISION; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; G1 PHASE; GENE EXPRESSION; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; S PHASE; TUMOR CELLS, CULTURED;

EID: 0034742488     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.15.8.1370     Document Type: Article

References (80)

1. Signaling pathways for vitamin D-induced differentiation: Implications for therapy of proliferative and neoplastic diseases
2. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens
3. 3 signalling
4. 3 receptor- and retinoid X receptor-mediated gene activation in vivo
5. 3-dependent cell-free transcription
6. 3 receptor in the context of the nuclear receptor superfamily
7. The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed
8. 3-regulated expression of the eukaryotic genome
9. The retinoblastoma protein pathway and the restriction point
10. Control of pRB phosphorylation
11. Inhibitors of mammalian G1 cyclin-dependent kinases
12. Principles of CDK regulation
13. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
14. INK4B is a potential effector of TGFβ-induced cell cycle arrest
15. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function
16. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
17. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins
18. Inhibition of cyclin-dependent kinases by p21
19. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase
20. Regulation of mammalian cyclin-dependent kinase 2
21. Regulation of cell proliferation by the E2F transcription factors
22. Toward an understanding of the functional complexity of the E2F and retinoblastoma families
23. INK4a, TGFβ, and contact inhibition
24. 3 leads to the induced differentiation of the myelomonocytic cell line U937
25. 3 in HL60 cells
26. 3-treated HL60 cells
27. Effect of a novel vitamin D3 analog, EB1089, on G1 cell cycle regulatory proteins in HL-60 cells
28. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
29. kip1 and E-cadherin
30. 3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells
31. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines
32. 3 and its analogue, EB1089, in human breast cancer cells
33. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells
34. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells
35. 3 effects on cell cycle
36. 3 and synthetic vitamin D3 analogues in a cell density-, calcium- and serum-dependent manner
37. 3 inhibitory effect on the growth of two human breast cancer cell lines (MCF-7, BT-20)
38. 3 analogues and tamoxifen
39. Differences in the mechanisms of growth control in contact-inhibited and serum-deprived human fibroblasts
40. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
41. A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation
42. Introduction to the E2F family: Protein structure and gene regulation
43. The cdk2 kinase is required for the G1-to-S transition in mammalian cells
44. Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase
45. 3: Past, present, and future
46. Cip1
47. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory mechanisms
48. Involvement of myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway
49. Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4
50. Transforming growth factor β stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells
51. CDK inhibitors: Positive and negative regulators of G1-phase progression
52. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4
53. Active cdk6 complexes re predominantly nuclear and represent only a minority of the cdk6 in T cells
54. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes
55. 1 arrest induced by ultraviolet irradiation
56. Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4
57. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGFβ in cells lacking the CDK inhibitor p15
58. Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation
59. Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition
60. Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite
61. Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells
62. 3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4
63. 3 stimulates activator protein-1-dependent caco-2 cell differentiation
64. 3
65. 3 in promyelocytic NB4 leukemia cells: A structure-function study
66. 3 and its analogues in rat osteoblast-like cells
67. Regulation of c-myc expression by Ras/Raf signalling
68. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells
69. Seocalcitol (EB 1089): A vitamin D analogue of anticancer potential. Background, design, synthesis, preclinical and clinical evaluation
70. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro
71. 3 analog, EB1089
72. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice
73. The adenovirus E1A-associated kinase consists of cyclin E- p33cdk2 and cyclin A-p33cdk2
74. 1 phase control in B-cell neoplasms carrying the t(11;14) translocation
75. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells
76. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity
77. D-type cyclin-dependent kinase activity in mammalian cells
78. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines
79. INK4A-mediated growth suppression